| Electronic Aci | knowledgement Receipt |
|--|---|
| EFS ID: | 6649992 |
| Application Number: | 10551205 |
| International Application Number: | |
| Confirmation Number: | 4092 |
| Title of Invention: | Oral formulations of cladribine |
| First Named Inventor/Applicant Name: | Nicholas S. Bodor |
| Customer Number: | 21839 |
| Filer: | Mary Katherine Baumeister/Diana Francis |
| Filer Authorized By: | Mary Katherine Baumeister |
| Attorney Docket Number: | 0056192-000024 |
| Receipt Date: | 16-DEC-2009 |
| Filing Date: | 14-NOV-2006 |
| Time Stamp: | 15:40:55 |
| Application Type: | U.S. National Stage under 35 USC 371 |
| Payment information: | |
| Submitted with Payment | yes |
| Payment Type | Credit Card |
| Payment was successfully received in RAM | \$180 |
| RAM confirmation Number | 2125 |
| Deposit Account | |
| Authorized User | |
| File Listing: | |
| | |

File Name

File Size(Bytes)/ Message Digest Multi

Part /.zip (if appl.)

Pages

Document

Number

Document Description

| | | Total Files Size (in bytes | 257 | 8931 | |
|--------------------|---|--|---|------|----|
| Information: | | | | | |
| Warnings: | | | b86076ccc91Sb1c0S2c62bd1c2d1c0tc6633 71100 | | |
| 7 | Fee Worksheet (PTO-875) | fee-info.pdf | 29880 b86076ccc915b1c052c62bdh2d1c0fc6633 | no | 2 |
| Information: | | | | | |
| Warnings: | · | · | | | |
| 6 | Foreign Reference | 005619224ref.pdf | 1864081 3848a30x436978462410f7265043b601e39 889a7 | no | 51 |
| This is not an U | SPTO supplied IDS fillable form | | | 1 | |
| Information: | | | | | |
| Warnings: | | | | | |
| 5 | Information Disclosure Statement (IDS) Filed (SB/08) | 0056192241449.pdf | a23e947132649ee8e8a119b6c07b06da495 987c8 | no | 1 |
| Information: | nformation: | | 64666 | | |
| Warnings: | | | | | |
| | 4 Transmittal Letter | 005619224lDS.pdf | 18cfesad62588dc7255a9s3c667ds5888593 914b | no | |
| 4 | | | 47767 | | 2 |
| Information: | | | | | |
| Warnings: | <u> </u> | | 1 | | |
| 3 | 3 Transmittal Letter | 005619224TLIDS.pdf | 9862/50233/5110dba0a61-095a0b8118-c1 b46d | no | 1 |
| | | 40409 | | | |
| Information: | | | | | |
| Warnings: | 2 Amendment/Req. Reconsideration-After Non-Final Reject | 005619224AMEND.pdf | 1cs21e4cbf/0b501cc1e58b52f53cbs/dd3a 6bfa | no | |
| 2 | | | 481410 | | 9 |
| Information: | | | | | |
| Warnings: | | | | | |
| i Hansimual Letter | 0036192241E.pdi | 9d3feab457f9e99bf8c54coec2a11d1ebd1a fi20 | .10 | | |
| 1 | Transmittal Letter | 005619224TL.pdf | 50718 | no | 1 |

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-[d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.